FDA Returns To MDUFA Table With High, Low Proposals
This article was originally published in The Gray Sheet
The priorities-gap between FDA and industry in MDUFA IV negotiations is narrowing. In May, the agency returned with counter-proposals that reduce user-fee increases compared to its prior plans, though there is still at least a $160m difference from the most recent proposal that is public from industry.
Register for our free email digests: